TCE Specialist CytoCares Makes Inroads Into Autoimmune Space

 
• By Dexter Jie Yan

CytoCares’ CEO shares plans for CC312, a potentially first-in-class trispecific antibody for autoimmune disorders it sees as differentiated from global rivals.

autoimmune disease
CytoCares aims to repurpose its T-cell engagers for the treatment of autoimmune diseases from cancers. • Source: Shutterstock

More from Clinical Trials

More from Scrip